{'Year': '2018', 'Month': 'Mar'}
An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
Anthracyclines are a class of highly effective chemotherapeutic drugs commonly used to treat cancer patients. Anthracyclines, however, are associated with the development of serious adverse reactions, including anthracycline-induced cardiotoxicity (ACT). It is not possible, within current practice, to accurately individualize treatment to minimize risk.